After creating antibody makers Apogee and Spyre, Paragon Therapeutics is back with another inflammatory and immune disease biotech, and the startup is immediately going to the public markets.
Spyre Therapeutics Announces $180 Million Private Placement
Spyre Therapeutics Announces Grants of Inducement Awards